Pharma Business - April 1, 2019
AstraZeneca’s Selumetinib granted Breakthrough Therapy Designation
AstraZeneca and MSD have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. This designation is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), […]
In a new job - May 8, 2016
Jacob Tellgren new Vice President & Global Brand Leader Diabetes
Jacob Tellgren has been appointed Vice President and Global Brand Leader Diabetes at Merck & Co at MSD’s headquarter in the US. Tellgren has been CEO of MSD Sweden since Januart 2014 and he is for example responsible for organizing MSD according to the healthcare regions and making the dialogue with the healthcare principals a high […]
Collaboration - February 10, 2016
MSD collaborates with Sahlgrenska Academy
MSD has signed a framework agreement with the Sahlgrenska Academy at the University of Gothenburg and the region Västra Götaland. The agreement is the starting point for a new collaboration arena which hopefully in the long run will benefit patients. The three collaboration partners will form a steering committee and initiate for example better identification […]
Clinical Trials - June 8, 2015
ALK Partner Testing Allergy Drug
ALK’s partner MSD has produced encouraging results from a North American Phase III clinical trial of ALK’s investigational sublingual allergy immunotherapy tablet for the treatment of house dust mite allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favor of HDM SLIT-tablet compared with placebo, according to BioSpace.com. The primary endpoint […]
Pharma Business - September 3, 2014
MSD changes location
Pharmaceutical company MSD is moving to the new Stockholm life science cluster. The company has been located in Sollentuna, outside of Stockholm, for the last 25 years but will change locations to Hagastaden during the spring of 2015. “For MSD in Sweden it is important to be part of the development of the new cluster […]
Collaboration - May 22, 2014
Collaboration between MSD and Stockholm County Council
The pharmaceutical company MSD has signed collaboration agreement with the Stockholm County Council. The parties have signed a letter of intent with the aim to achieve better quality of health care in Stockholm, especially regarding therapy areas where there is a growing need for improved treatment or diagnostics. “In Sweden there is a unique health […]
